Paper28325865
Venetoclax and obinutuzumab in chronic lymphocytic leukemia.
Fischer K and 26 others. Blood, 2017. Cited by 101 papers, by iCite.
Cite this record
ConductScience Library. Venetoclax and obinutuzumab in chronic lymphocytic leukemia. Papers, record 28325865. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28325865
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibodies, Monoclonal, Humanized | Major topic |
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Bridged Bicyclo Compounds, Heterocyclic | Major topic |
| Leukemia, Lymphocytic, Chronic, B-Cell | Major topic |
| Sulfonamides | Major topic |
| Aged | |
| Aged, 80 and over | |
| Female | |
| Humans | |
| Male | |
| Middle Aged |
Source PubMed
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Erratum in | 28705863 | Fischer K, Al-Sawaf O, Fink A-M, et al. Venetoclax and obinutuzumab in chronic lymphocytic leukemia. Blood. 2017;129(19):2702-2705. | https://conductscience.org/library/papers/28705863 |
Source PubMed
References9
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 26639348 | Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. | N Engl J Med | 2016 | https://conductscience.org/library/papers/26639348 | PubMed |
| 2 | 27178240 | Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. | Lancet Oncol | 2016 | https://conductscience.org/library/papers/27178240 | PubMed |
| 3 | 23291630 | ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. | Nat Med | 2013 | https://conductscience.org/library/papers/23291630 | PubMed |
| 4 | 26472752 | Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia. | Blood | 2016 | https://conductscience.org/library/papers/26472752 | PubMed |
| 5 | 24401022 | Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. | N Engl J Med | 2014 | https://conductscience.org/library/papers/24401022 | PubMed |
| 6 | 22331940 | Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. | J Clin Oncol | 2012 | https://conductscience.org/library/papers/22331940 | PubMed |
| 7 | 28089635 | Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. | Lancet Oncol | 2017 | https://conductscience.org/library/papers/28089635 | PubMed |
| 8 | 22591390 | Therapy of elderly/comorbid patients with chronic lymphocytic leukemia. | Curr Pharm Des | 2012 | https://conductscience.org/library/papers/22591390 | PubMed |
| 9 | 27573660 | Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group. | J Clin Oncol | 2016 | https://conductscience.org/library/papers/27573660 | PubMed |
Cited by59
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 101 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41978941 | Transition Into Clinical Routine and Survival Outcomes of BCL2- and BTK Inhibitors: An Analysis of Patient Data From the GCLLSG Registry. | Eur J Haematol | 2026 | https://conductscience.org/library/papers/41978941 | PubMed |
| 41681925 | The Phase Ib VenObi CNS Study: Chemotherapy-Free Treatment with Venetoclax and Obinutuzumab for Relapsed/Refractory Primary Large B-Cell Lymphoma of the Central Nervous System. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/41681925 | PubMed |
| 41368078 | Functional differences between CLL- and ALL-derived CAR T cells in a 3D tumor microenvironment highlight CXCR4 and IL-10 as potential modulatory targets. | Hemasphere | 2025 | https://conductscience.org/library/papers/41368078 | PubMed |
| 39871707 | Chronic Lymphocytic Leukemia: 2025 Update on the Epidemiology, Pathogenesis, Diagnosis, and Therapy. | Am J Hematol | 2025 | https://conductscience.org/library/papers/39871707 | PubMed |
| 39060763 | Combination of BCL-2 inhibitors and immunotherapy: a promising therapeutic strategy for hematological malignancies. | Discov Oncol | 2024 | https://conductscience.org/library/papers/39060763 | PubMed |
| 38835348 | Advancing CAR T-cell therapy for chronic lymphocytic leukemia: exploring resistance mechanisms and the innovative strategies to overcome them. | Cancer Drug Resist | 2024 | https://conductscience.org/library/papers/38835348 | PubMed |
| 37686667 | The Five "Ws" of Frailty Assessment and Chronic Lymphocytic Leukemia: Who, What, Where, Why, and When. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37686667 | PubMed |
| 36334238 | A Probabilistic Cost-Effectiveness Analysis of Venetoclax and Obinutuzumab as a First-Line Therapy in Chronic Lymphocytic Leukemia in Canada. | Pharmacoecon Open | 2023 | https://conductscience.org/library/papers/36334238 | PubMed |
| 35983732 | Utility of measurable residual disease for predicting treatment outcomes with BCR- and BCL2-Targeted therapies in patients with CLL. | Leuk Lymphoma | 2022 | https://conductscience.org/library/papers/35983732 | PubMed |
| 35309786 | Combining novel agents in chronic lymphocytic leukemia: Greater than the sum of its parts? | Hemasphere | 2019 | https://conductscience.org/library/papers/35309786 | PubMed |
| 35066728 | Venetoclax combined with hypomethylating agents or low-dose cytarabine as induction chemotherapy for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review and meta-analysis. | Clin Exp Med | 2023 | https://conductscience.org/library/papers/35066728 | PubMed |
| 34943974 | Killing by Degradation: Regulation of Apoptosis by the Ubiquitin-Proteasome-System. | Cells | 2021 | https://conductscience.org/library/papers/34943974 | PubMed |
| 34938664 | Venetoclax Shows Low Therapeutic Activity in BCL2-Positive Relapsed/Refractory Peripheral T-Cell Lymphoma: A Phase 2 Study of the Fondazione Italiana Linfomi. | Front Oncol | 2021 | https://conductscience.org/library/papers/34938664 | PubMed |
| 34733320 | Development of a 3 RNA Binding Protein Signature for Predicting Prognosis and Treatment Response for Glioblastoma Multiforme. | Front Genet | 2021 | https://conductscience.org/library/papers/34733320 | PubMed |
| 34168283 | Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations. | Leukemia | 2021 | https://conductscience.org/library/papers/34168283 | PubMed |
| 33578607 | Double remission of chronic lymphocytic leukemia and secondary acute myeloid leukemia after venetoclax monotherapy: A case report. | Medicine (Baltimore) | 2021 | https://conductscience.org/library/papers/33578607 | PubMed |
| 33519195 | Oncologist and Patient Preferences for Novel Agents in First-Line Treatment for Chronic Lymphocytic Leukemia: Commonalities and Disconnects. | Patient Prefer Adherence | 2021 | https://conductscience.org/library/papers/33519195 | PubMed |
| 33275668 | Chemotherapy-free frontline therapy for CLL: is it worth it? | Hematology Am Soc Hematol Educ Program | 2020 | https://conductscience.org/library/papers/33275668 | PubMed |
| 32934355 | Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia. | Leukemia | 2021 | https://conductscience.org/library/papers/32934355 | PubMed |
| 32542586 | Frontline Therapy of Chronic Lymphocytic Leukemia: Changing Treatment Paradigm. | Curr Hematol Malig Rep | 2020 | https://conductscience.org/library/papers/32542586 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/28325865
GET https://conductscience.org/api/papers/v1/28325865/authors?page=2